2-(pyridin-2-yldisulfanyl)ethyl (6-(trifluoromethyl)-1H-benzo[d][1,2,3]triazol-1-yl) carbonate | 742091-98-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 2-(pyridin-2-yldisulfanyl)ethyl (6-(trifluoromethyl)-1H-benzo[d][1,2,3]triazol-1-yl) carbonate
• 英文别名: 2-(Pyridin-2-yldisulfanyl)ethyl [6-(trifluoromethyl)benzotriazol-1-yl] carbonate
• CAS: 742091-98-1
• 化学式: C₁₅H₁₁F₃N₄O₃S₂
• 分子量: 416.405
• InChiKey: FGTNNFIDBTZZEY-UHFFFAOYSA-N

物化性质

• 沸点：
  513.2±60.0 °C(Predicted)
• 密度：
  1.56±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  130
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2-(pyridin-2-yldisulfanyl)ethyl (6-(trifluoromethyl)-1H-benzo[d][1,2,3]triazol-1-yl) carbonate 、 丝裂霉素 C 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以50%的产率得到2-(pyridin-2-yldisulfanyl)ethyl (1aS,8S,8aR,8bS)-6-amino-8-((carbamoyloxy)methyl)-8a-methoxy-5-methyl-4,7-dioxo-1a,4,7,8,8a,8b-hexahydroazirino[2’,3’:3,4]pyrrolo[1,2-a]indole-1(2H)-carboxylate
  参考文献：
  名称：

  [EN] MITOMYCIN C PRODRUG LIPOSOME FORMULATIONS AND USES THEREOF
  [FR] FORMULATIONS DE LIPOSOME DE PROMÉDICAMENT DE MITOMYCINE C ET LEURS UTILISATIONS

  摘要：

  本发明提供了用于治疗癌症的MMC前药化合物和脂质体MMC前药及其组合物。该组合物包括含有磷脂酰胆碱脂质、固醇、PEG-脂质和MMC前药的脂质体。本发明还提供了用于治疗癌症的脂质体组合物，包括向需要的患者施用脂质体，其中脂质体包括：磷脂酰胆碱脂质；固醇；PEG-脂质和MMC前药或其药用可接受的盐。

  公开号：

  WO2018089481A1
• 作为产物：
  描述：

  1-羟基-6-(三氟甲基)苯并三唑 以 乙醚 、 乙腈 为溶剂， 反应 39.17h， 生成 2-(pyridin-2-yldisulfanyl)ethyl (6-(trifluoromethyl)-1H-benzo[d][1,2,3]triazol-1-yl) carbonate
  参考文献：
  名称：

  [EN] METHOD OF TREATING CANCER BY TARGETING MYELOID-DERIVED SUPPRESSOR CELLS
  [FR] PROCÉDÉ DE TRAITEMENT DU CANCER PAR CIBLAGE DE CELLULES SUPPRESSIVES D'ORIGINE MYÉLOÏDE

  摘要：

  本发明涉及使用一种或多种包含通过连接剂连接的叶酸受体结合配体的药物来治疗癌症的方法。更具体地说，本发明涉及使用一种或多种包含通过连接剂连接的叶酸受体结合配体的药物来治疗癌症，以靶向骨髓源性抑制细胞。

  公开号：

  WO2017205661A1

文献信息

• [EN] BIVALENT LINKERS AND CONJUGATES THEREOF<br/>[FR] GROUPES DE LIAISON BIVALENTS ET CONJUGUÉS DE CEUX-CI
  申请人：ENDOCYTE INC

  公开号：WO2006012527A1

  公开（公告）日：2006-02-02

  Bivalent linkers derived from compounds of formulae (V), (VI) and (VII), where X1 and X2 are leaving groups and the other variables are as defined in the claims, to be included in or for preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates are described.

  从公式（V）、（VI）和（VII）的化合物中衍生出的双价连接剂，其中X1和X2是离去基团，其他变量如索权中定义的那样，可用于或用于制备维生素、药物、诊断剂和/或成像剂的结合物。
• [EN] METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT<br/>[FR] PROCÉDÉS D'AMÉLIORATION DE THÉRAPIES CELLULAIRES MODIFIÉES DANS LE TRAITEMENT DU CANCER
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2022147576A1

  公开（公告）日：2022-07-07

  Methods are provided for reprogramming M2 -like macrophages to Ml -like macrophages, which reverses the proinflammatory to anti-inflammatory shift observed during the course of certain cancers, co-administered with one or more types of engineered cells such as, without limitation, CAR T-cells, engineered natural killer cells, engineered stem cells or the like. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and/or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for cancers.

  提供了一种将M2型巨噬细胞重新编程为M1型巨噬细胞的方法，这可以逆转某些癌症过程中观察到的促炎症到抗炎症的转变，与一种或多种工程细胞（例如CAR T细胞，工程自然杀伤细胞，工程干细胞等）共同使用。这些化合物包括一个免疫调节剂，其靶向细胞的模式识别受体，并通过纳入靶向基团（例如叶酸或其功能性片段或类似物）特异性地作用于感兴趣的细胞。可以包括可释放和/或不可释放的连接剂，并设计为促进免疫调节剂的最佳输送。这些化合物和组合物可以用于一个或多个癌症治疗方法。
• Bivalent linkers and conjugates thereof
  申请人：Endocyte, Inc.

  公开号：US10647676B2

  公开（公告）日：2020-05-12

  This invention pertains to bivalent linkers, and the synthesis and use thereof. In particular, this invention pertains to the synthesis and use of bivalent linkers in preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates. The present invention includes divalent linkers, which are alternatively referred to as bivalent linkers, that may be used to couple, link, bond, attach, or otherwise associate two or more chemical entities. This coupling, linking, attachment, or association may be used in the formation of conjugates of such chemical entities. Those chemical entities include targeting ligands and receptor-binding ligands, such as vitamins. Those chemical entities also include drugs for treating various diseases or disease states, and imaging and diagnostic agents for diagnosing, detecting, or otherwise monitoring various diseases or disease states.

  本发明涉及二价连接体及其合成和使用。特别是，本发明涉及二价连接体在制备维生素、药物、诊断剂和/或成像剂共轭物中的合成和使用。本发明包括二价连接体，也可称为二价连接体，可用于耦合、连接、键合、附着或以其它方式连接两个或多个化学实体。这种偶联、连接、附着或联合可用于形成此类化学实体的共轭物。这些化学实体包括靶向配体和受体结合配体，如维生素。这些化学实体还包括用于治疗各种疾病或疾病状态的药物，以及用于诊断、检测或以其他方式监测各种疾病或疾病状态的成像剂和诊断剂。
• WO2021007277A5
  申请人：——

  公开号：WO2021007277A5

  公开（公告）日：2023-07-14
• Design and synthesis of releasable folate–drug conjugates using a novel heterobifunctional disulfide-containing linker
  作者：Apparao Satyam

  DOI：10.1016/j.bmcl.2008.04.063

  日期：2008.6

  Cellular uptake of vitamin folic acid occurs via folate-receptor mediated endocytosis. Many types of cancer cells express high levels of folate receptors as they need continuous supply of this vitamin for their proliferation. With an objective to use folic acid as a 'Trojan Horse' to transport anticancer drugs into cancer cells, a novel heterobifunctional disulfide-containing linker was synthesized and utilized to covalently link an amino-and hydroxyl-containing anticancer drug, and an appropriately functionalized folic acid to create novel targetable folate-drug conjugates that are shown to release free drugs under biologically relevant pH via sulfhydryl-assisted cleavage of the self-immolative disulfide-containing linker. (C) 2008 Elsevier Ltd. All rights reserved.